Millipore Sigma Vibrant Logo
Attention: We have moved. EMD Millipore products are no longer available for purchase on emdmillipore.com.Learn More

480420 NF449 - CAS 627034-85-9 - Calbiochem

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
627034-85-9C₄₁H₂₄N₆O₂₉S₈ · 8Na

Products

Catalog NumberPackaging Qty/Pack
480420-10MG Glass bottle 10 mg
Description
OverviewA potent Gsα-subunit-selective G-protein antagonist. Suppresses the rate of GTPγS binding to Gsα-s-subunit (IC50 = 140 nM) but not to Giα-1-subunit. Inhibits stimulation of adenylate cyclase activity in S49 cyc- cells (which lack endogenous Gsα-subunit) by exogenously added Gsα-subunit. Also blocks the coupling of β-adrenergic receptors to Gs (EC50 = 7.9 µM).
Catalogue Number480420
Brand Family Calbiochem®
Synonyms4,4ʹ,4ʹʹ,4ʹʹʹ-[Carbonyl-bis[imino-5,1,3-benzenetriyl bis-(carbonylimino)]]tetrakis-(benzene-1,3-disulfonic Acid, 8Na)
References
ReferencesHulsmann, M., et al. 2003. Eur. J. Pharmacol. 470, 1.
Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
Product Information
CAS number627034-85-9
ATP CompetitiveN
FormWhite solid
Hill FormulaC₄₁H₂₄N₆O₂₉S₈ · 8Na
Chemical formulaC₄₁H₂₄N₆O₂₉S₈ · 8Na
Hygroscopic Hygroscopic
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
ApplicationNF449, CAS 627034-85-9, is a potent Gsα-subunit-selective G-protein antagonist. Suppresses GTPγS binding to Gsα-s-subunit (IC50 = 140 nM). A highly potent P2X1 receptor antagonist (IC50 = 280 pM).
Biological Information
Primary TargetGsα-subunit-selective G-protein antagonist
Primary Target IC<sub>50</sub>140 nM suppressing the rate of GTPγS binding to Gsα-s-subunit
Purity≥95% by HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Identification Number
Catalog Number GTIN
480420-10MG4055977201369

Documentation

NF449 - CAS 627034-85-9 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

NF449 - CAS 627034-85-9 - Calbiochem Certificates of Analysis

TitleLot Number
480420

References

Reference overview
Hulsmann, M., et al. 2003. Eur. J. Pharmacol. 470, 1.
Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision30-November-2020 JSW
Synonyms4,4ʹ,4ʹʹ,4ʹʹʹ-[Carbonyl-bis[imino-5,1,3-benzenetriyl bis-(carbonylimino)]]tetrakis-(benzene-1,3-disulfonic Acid, 8Na)
DescriptionA potent G-selective G-protein antagonist. Suppresses the rate of GTPγS binding to Gsα-s (IC50 = 140 nM) but not in Giα-1. Inhibits stimulation of adenylate cyclase activity in S49 cyc cells (which lack endogenous G) by exogenously added Gsα-s. Also blocks the coupling of β-adrenergic receptors to Gs (EC50 = 7.9 µM). Acts as a reversible competitive antagonist of the human P2X receptor, exhibiting much higher potency at human P2X(1) than at P2X(7) receptors (IC50 = 50 nM vs 40 µM respectively).
FormWhite solid
CAS number627034-85-9
Chemical formulaC₄₁H₂₄N₆O₂₉S₈ · 8Na
Structure formulaStructure formula
Purity≥95% by HPLC
SolubilitydH₂O (100 mg/ml)
Storage Protect from light
+2°C to +8°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesHulsmann, M., et al. 2003. Eur. J. Pharmacol. 470, 1.
Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.